Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
Healthcare
$70.75 +2.45%
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
52W Low $29.18High $105.00
Volume 0.10M
Average 0.17M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$12.20M
FY 2025 · Annual
Investing Cash Flow
-$63.45M
FY 2025 · Annual
Financing Cash Flow
$91.57M
FY 2025 · Annual
+54.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.47M | 1.64M | 1.9M | 1.14M | 4.84M |
| Change in Working Capital | 317.77K | 1.65M | (1.35M) | 3.49M | (2.61M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 403.97K | 1.48M | (1.33M) | 506.79K | 388.22K |
| Other Working Capital | (86.2K) | 167.52K | (20.41K) | 2.98M | (2.99M) |
| Other Non-Cash Items | 0 | 0 | 0 | 4.55M | (716.46K) |
| Operating Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
| Capital Expenditures | 1 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (4.92M) | (7.88M) | (15.32M) | (87.15M) |
| Sales of Investments | 0 | 0 | 12.81M | 985.73K | 23.7M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.92M) | 4.93M | (14.34M) | (63.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.93M | 109.34K | 2.07M | 59.4M | 127.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (35M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45.78K) | (76.46K) | (46.97K) | (104.14K) | (1.13M) |
| Financing Cash Flow | 10.88M | 32.87K | 2.03M | 59.29M | 91.57M |
| Effect of Forex Changes | 4.62K | (3.48K) | (16.8K) | 494 | 97.27K |
| Net Change in Cash | 3.57M | (12.12M) | (920.11K) | 38.55M | 16.02M |
| Free Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$13.7M
+ D&A$0
+ Stock-Based Comp$4.8M
+ Deferred Tax$0
- Working Capital-$2.6M
- Other Non-Cash-$716.5K
= Operating Cash Flow-$12.2M
- Capex$0
= Free Cash Flow-$12.2M
Analysis
FY2025 free cash flow is -$12.2M. FCF conversion is 89.0% of net income. Operating cash flow was -$12.2M, with capex of $0. The largest bridge item is Stock-Based Comp at $4.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 |
Does MNPR generate free cash flow?
Monopar Therapeutics Inc. (MNPR) generated -$12.20M of free cash flow in fiscal 2025.
How much operating cash flow does MNPR produce?
Operating cash flow was -$12.20M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.